Instead, the FDA granted Aduhelm a conditional approval, allowing it to be prescribed and used while Biogen conducts a post-marketing, phase 4 confirmatory study – which could take years to ...

The FDA "has failed in its responsibility to protect patients and families from unproven treatments with known harms" in approving Biogen's Alzheimer's disease drug Aduhelm. That was the damning ...